Search Results for “EC” – Page 560 – media

GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma

GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
- Source: us.gsk
- 865
- March 12, 2018
asthma EC GSK Relvar Ellipta
Health app adoption tripled since 2014, Accenture survey finds

Use of telemedicine has gone up as well, but not as dramatically, respondents say.
- Source: HealthcareITNews
- 979
- March 12, 2018
digital health Market Views mHealth
Five tips for exploring pharmaceutical drug export markets

For pharmaceutical companies who want to explore international markets, identifying these target markets is the first step. Being able to pinpoint the right target market, will increase the probability for more business deals. In order to help you with this process, we have listed 5 of the more important aspects to consider.
- Source: Ddu
- 803
- March 9, 2018
Ddu College pharmaceutical
Epigenetic Dysregulation May Be Key to Onset

Greater than 90% of all Alzheimer’s disease (AD) cases are sporadic, meaning there are few hereditary risk factors for developing the disease. Although certain genetic variants increase the risk of AD, age is the strongest known risk factor. Yet, understanding how the underlying molecular mechanisms of aging predispose individuals to AD has remained elusive. Now, a team of researchers from the Perelman School of Medicine at the University of Pennsylvania have discovered what they believe are changes to the normal epigenetic landscape that lead to the onset of Alzheimer’s.
- Source: Pixabay
- 581
- March 9, 2018
Alzheimer's Researches
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant Including First-Ever Phase 3 Head-to-Head Superiority Comparison Versus Zolpidem ER in Patients With Sleep Disorder

Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant, an investigational agent for sleep and wake regulation currently being studied for the treatment of multiple sleep disorders.
- Source: finance.yahoo.
- 526
- March 9, 2018
Clinical Trials Eisai lemborexant multiple sleep disorders
Prometic Snags Rare Pediatric Disease Designation from the FDA for its Inter-Alpha-Inhibitor-Proteins

Shares of Laval, Quebec-based ProMetic Life Sciences Inc. jumped more than 8.7 percent this morning after securing the U.S. Food and Drug Administration’s Rare Pediatric Disease Designation for its Inter-Alpha-Inhibitor-Proteins (IAIP) treatment for necrotizing enterocolitis (NEC).
- Source: biospace
- 600
- March 9, 2018
FDA NEC
J&J CIO touches on FDA pre-cert pilot program, artificial intelligence and innovation

Stuart McGuigan took on his role as CIO of industry behemoth Johnson & Johnson in 2012. That was around the same time that Alex Gorsky joined the company as CEO. Since then, part of Gorsky’s mission has been to help J&J focus on technology, McGuigan said in an interview at HIMSS this week.
- Source: MedCityNews
- 678
- March 9, 2018
AI Company Insight healthcare technologies and innovations
Panther gets FDA nod for bone fixation device

Panther Orthopedics has won FDA approval for its implantable orthopedic fixation device. The 510(k) nod clears Panther to sell a device designed to deliver continuous compression during bone healing while allowing joint motion.
- Source: FierceBioTech
- 508
- March 9, 2018
Company Insight medical device products Orthopaedics
FDA approves new HIV treatment for patients who have limited treatment options

Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV). Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.
- Source: Prnewswire
- 482
- March 8, 2018
antiretroviral HIV New Approvals
Celgene Completes Acquisition of Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy

Celgene Corporation (NASDAQ:CELG) today announced that it has completed the acquisition of Juno Therapeutics, Inc. As a result, the common stock of Juno will no longer be listed for trading on the NASDAQ Global Select Market.
- Source: ir.celgene
- 585
- March 8, 2018
cellular immunotherapy Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.